Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Main Authors: | Can G. Leineweber, Miriam Rabehl, Anne Pietzner, Nadine Rohwer, Michael Rothe, Maciej Pech, Bruno Sangro, Rohini Sharma, Chris Verslype, Bristi Basu, Christian Sengel, Jens Ricke, Nils Helge Schebb, Karsten-H. Weylandt, Julia Benckert |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1354581/full |
Similar Items
-
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
by: Can G. Leineweber, et al.
Published: (2023-03-01) -
Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma
by: Can G. Leineweber, et al.
Published: (2020-03-01) -
Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia
by: Yanan Xiao, et al.
Published: (2023-08-01) -
Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins
by: Chaoxuan Wang, et al.
Published: (2024-03-01) -
Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids
by: Nadine Rohwer, et al.
Published: (2023-08-01)